Lausanne-based Court of Arbitration for Sport (CAS) has reduced the two-year tennis ban for doping on Maria Sharapova to 15 months.
The Russian player tested positive for the banned medication meldonium during January’s Australian Open.
In its verdict the CAS “found that Ms Sharapova committed an anti-doping rule violation and that while it was with ‘no significant fault’, she bore some degree of fault, for which a sanction of fifteen months is appropriate”.
Sharapova openly admitted she had been taking meldonium for 10 years to help treat illnesses, a heart issue and a magnesium deficiency.
She also claimed it had entirely escaped her attention that the product had been added to the banned substance list published by the World Anti-Doping Agency (WADA) on January 1, just before the Australian Open.
The initial ban was imposed by an independent tribunal appointed by the International Tennis Federation and the reduced ban following her appeal means the Russian, who has spent most of her life in the United States, will be free to resume competition at the end of April 2017.